Related Experiment Video
Updated: Sep 1, 2025

Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases
Marta Soto1,2, Alex Iranzo2,3, Sara Lahoz4,5
1Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
Background:
Isolated rapid eye movement sleep behavior disorder (IRBD) is a well-established clinical risk factor for Lewy body diseases (LBDs), such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
Objective:
To elucidate whether serum microRNA (miRNA) deregulation in IRBD can antedate the diagnosis of LBD by performing a longitudinal study in different progression stages of IRBD before and after LBD diagnosis and assessing the predictive performance of differentially expressed miRNAs by machine learning-based modeling.
Methods:
Using genome-wide miRNA analysis and real-time quantitative polymerase chain reaction validation, we assessed serum miRNA profiles from patients with IRBD stratified by dopamine transporter (DaT) single-photon emission computed tomography into DaT-negative IRBD (n = 17) and DaT-positive IRBD (n = 21), IRBD phenoconverted into LBD (n = 13), and controls (n = 20). Longitudinally, we followed up the IRBD cohort by studying three time point serum samples over 26 months.
Results:
We found sustained cross-sectional and longitudinal deregulation of 12 miRNAs across the RBD continuum, including DaT-negative IRBD, DaT-positive IRBD, and LBD phenoconverted IRBD (let-7c-5p, miR-19b-3p, miR-140, miR-22-3p, miR-221-3p, miR-24-3p, miR-25-3p, miR-29c-3p, miR-361-5p, miR-425-5p, miR-4505, and miR-451a) (false discovery rate P < 0.05). Age- and sex-adjusted predictive modeling based on the 12 differentially expressed miRNA biosignatures discriminated IRBD and PD or DLB from controls with an area under the curve of 98% (95% confidence interval: 89-99%).
Conclusions:
Besides clinical diagnosis of IRBD or imaging markers such as DaT single-photon emission computed tomography, specific miRNA biosignatures alone hold promise as progression biomarkers for patients with IRBD for predicting PD and DLB clinical outcomes. Further miRNA studies in other PD at-risk populations, such as LRRK2 mutation asymptomatic carriers or hyposmic subjects, are warranted. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Insights
Serum microRNA (miRNA) signatures can predict Lewy body disease (LBD) development in individuals with isolated rapid eye movement sleep behavior disorder (IRBD). These 12 specific miRNAs show promise as early biomarkers for Parkinson
Area of Science:
- Neuroscience
- Genetics
- Biomarker Discovery
Background:
- Isolated rapid eye movement sleep behavior disorder (IRBD) is a known precursor to Lewy body diseases (LBDs), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
- Early identification of LBD risk in IRBD patients is crucial for timely intervention and management.
- Understanding the molecular changes preceding LBD diagnosis is essential for developing predictive biomarkers.
Purpose of the Study:
- To investigate serum microRNA (miRNA) deregulation in IRBD patients at different stages of LBD progression.
- To assess the predictive performance of differentially expressed miRNAs for LBD development using machine learning.
- To determine if miRNA profiles can antedate LBD diagnosis in individuals with IRBD.
Main Methods:
- Genome-wide miRNA analysis and real-time quantitative PCR validation were employed.
- Serum samples from IRBD patients (DaT-negative, DaT-positive, and phenoconverted to LBD) and controls were analyzed.
- A longitudinal follow-up of the IRBD cohort over 26 months was conducted with three time-point serum samples.
Main Results:
- Twelve specific miRNAs (let-7c-5p, miR-19b-3p, miR-140, miR-22-3p, miR-221-3p, miR-24-3p, miR-25-3p, miR-29c-3p, miR-361-5p, miR-425-5p, miR-4505, and miR-451a) showed sustained deregulation across the IRBD continuum.
- Machine learning models based on these 12 miRNAs accurately discriminated between IRBD/LBD patients and controls (AUC 98%).
- The identified miRNA biosignatures demonstrated significant predictive performance for LBD clinical outcomes.
Conclusions:
- Specific serum miRNA biosignatures are promising progression biomarkers for IRBD patients at risk of developing PD or DLB.
- These miRNA profiles hold potential for predicting clinical outcomes in IRBD, complementing existing diagnostic methods.
- Further research into miRNA biomarkers in other at-risk populations is warranted.
More Related Videos
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
Related Concept Videos
REM Sleep Behavior Disorder
RBD is significantly associated with...
Neural Regulation
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge: